SINTX Technologies Reassesses Exclusive Patent License with O2TODAY
August 05 2021 - 1:02PM
SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or
the “Company”), an original equipment manufacturer of advanced
ceramics for medical and non-medical applications, announced today
that it is reassessing the exclusive Patent License Agreement with
O2TODAY in light of O2TODAY’s decision to delay launch of its
SiNPRO filters and masks.
On Thursday, O2TODAY shared that it has been
made aware of regulatory requirements that prevent the distribution
of its antiviral masks and filters and is refunding pre-orders.
Given this new information, SINTX is considering a return to its
initial joint development efforts with O2TODAY and revaluating all
avenues of how it will bring the antipathogenic facemask technology
to market.
The development and manufacture of antiviral
face masks incorporated with SINTX silicon nitride is one component
of SINTX’s broader business strategy of developing several
antipathogenic fabric applications, including surgical gowns,
drapes, scrub suits, and related products for medical
personnel.
About SINTX Technologies, Inc.
SINTX Technologies is an OEM ceramics company
that develops and commercializes advanced ceramics for medical and
non-medical applications. The core strength of SINTX Technologies
is the manufacturing, research, and development of ceramics for
external partners. The Company presently manufactures advanced
ceramics powders and components in its FDA registered, ISO
13485:2016 certified, and ASD9100D certified manufacturing
facility.
For more information on SINTX Technologies
or its advanced ceramics material platform, please
visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (PSLRA) that are subject to a number of risks
and uncertainties. Risks and uncertainties that may cause such
differences include, among other things: the Company and its
partners may not be successful in the application of silicon
nitride powder into fabrics and the subsequent development of
products from those fabrics in a manner that will prove be to be
safe and effective for their intended uses and functions;
regulatory clearance to use products in which silicon nitride has
been applied to enhance antipathogenic properties may be lengthy
and expensive; volatility in the price of SINTX’s common stock; the
uncertainties inherent in new product development, including the
cost and time required to commercialize such product(s); market
acceptance of our products once commercialized; SINTX’s ability to
raise funding and other competitive developments. Readers are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date on which they are made
and reflect management’s current estimates, projections,
expectations and beliefs. There can be no assurance that any of the
anticipated results will occur on a timely basis or at all due to
certain risks and uncertainties, a discussion of which can be found
in SINTX’s Risk Factors disclosure in its Annual Report on Form
10-K, filed with the Securities and Exchange Commission (SEC) on
March 22, 2021, and in SINTX’s other filings with the SEC. SINTX
disclaims any obligation to update any forward-looking statements.
SINTX undertakes no obligation to publicly revise or update the
forward-looking statements to reflect events or circumstances that
arise after the date of this report.
Business Inquiries for SINTX:SINTX
Technologies801.839.3502IR@sintx.com
Media Inquiries for SINTX: Amanda Barry
Director of PR and ContentThe Summit Group abarry@summitslc.com
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Mar 2024 to Apr 2024
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Apr 2023 to Apr 2024